April 21, 2018
Rose
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million.
from MobiHealthNews https://ift.tt/2qNv5KM
April 21, 2018
Rose
MobiHealthNews
No comments
Related Posts:
Greenstein departs HHS and more digital health hires and departures- Blink Health alleges MedImpact improperly steers patients toward opioids
- Health outcomes AI company OM1 lands $21M in Series B funding
- Alphabet's GV invests $7 million in AI startup Owkin
- Virtual, in-person visits lead to similar blood pressure control for hypertension patients
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment